Greenhaven Road Capital released its Q3 2025 investor letter, reporting a -9% return for the quarter and YTD. Factors affecting the portfolio included a lack of AI investments, no overlap with S&P 500 or Russell 2000, and insufficient ownership of small, high-growth, unprofitable companies driving recent rallies.

Cellebrite DI Ltd. (NASDAQ: CLBT) was highlighted in Greenhaven Road Capital’s Q3 2025 letter. The Israeli software company saw a -21.27% one-month return, with shares losing 16.17% over 52 weeks. On Nov 7, 2025, CLBT closed at $15.40 per share, with a $3.765 billion market cap.

Greenhaven Road Capital noted in its Q3 2025 letter that Cellebrite DI Ltd. (NASDAQ: CLBT) was down for the year due to declining software multiples. Altimeter Capital data showed a 26% decline in EV/N12M Revenue for medium growth software companies, impacting CLBT and others in the sector.

Cellebrite DI Ltd. (NASDAQ: CLBT) is not among the 30 Most Popular Stocks Among Hedge Funds, but 38 hedge fund portfolios held the stock in Q2 2025. CLBT reported $113.3 million in Q2 2025 revenue, up 18% YoY driven by 21% subscription revenue growth. Despite potential, some AI stocks offer greater upside with less downside risk.

Read more at Yahoo Finance: Here’s Greenhaven Road Capital’s Views on Cellebrite (CLBT)